Richard B Silverman

USPTO Granted Patents = 107 (Patent Applications = 17)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 19)

Average Co-Inventor Count = 2.9

ph-index = 12

Forward Citations = 672(Granted Patents)

Forward Citations (Not Self Cited) = 414(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Chicago, IL (US) (1985 - 1986)
Morton Grove, MI (US) (1998)
Morton Grove, IL (US) (1996 - 2003)
Northbrook, IL (2012)
Northbrook, IL (US) (2001 - 2018)
Evanston, IL (US) (2020 - 2022)
Winnetka, IL (US) (2014 - 2024)

Company Filing History:

95 out of 2,117

Northwestern University

patents

8 out of 2,538

Warner-lambert Company

patents

4 out of 4

Cambria Pharmaceuticals, Inc.

patents

4. 2 out of 15,462

University of California

patents

5. 2 out of 169

Hadasit Medical Research Services and Development Ltd.

The General Hospital Corporation

patents

8. 1 out of 7

Lysosomal Therapeutics Inc.

patents

9. 1 out of 2

Catalyst Pharmaceutical Partners, Inc.

patents

10. 1 out of 348

Brookhaven Science Associates, Lcc

patents

11. 1 out of 10

Bial - R&d Investments, S.a.

patents

12. 1 out of 915

The University of Chicago

patents

13. 1 out of 504

Albert Einstein College of Medicine

patents

14. 9 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...

Areas of Expertise:

Nitric Oxide Synthase Inhibitors

Gaba Aminotransferase Inactivators

Pyrimidine Compounds

Cyclopentene Carboxylic Acids

Glucocerebrosidase Modulation

Aminotransferase Inhibitors

Amyotrophic Lateral Sclerosis Treatment

Toxoplasmosis Treatment

Selective Calcium Channel Antagonists

Chiral Synthesis

Neuronal Inhibitors

Bacterial Inhibitors

107 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492164 - Fluorine substituted cyclohexene analogues of gamma-aminobutyric acid (GABA) (2025-12-09),

2. 12331006 - Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (2025-06-17),

3. 12291533 - Substituted fused pyrimidine compounds and uses thereof (2025-05-06),

4. 12240815 - Potent and selective human neuronal nitric oxide synthase inhibitors (2025-03-04),

5. 12213973 - Bacterial nitric oxide synthase inhibitors (2025-02-04),

6. 12083113 - Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients (2024-09-10),

7. 11993569 - 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases (2024-05-28),

8. 11439632 - Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients (2022-09-13),

9. 11351173 - Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders (2022-06-07),

10. 11207283 - Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria (2021-12-28),

11. 11203596 - Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity (2021-12-21),

12. 11078153 - 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase (2021-08-03),

13. 10934270 - Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity (2021-03-02),

14. 10882865 - Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity (2021-01-05),

15. 10836708 - Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (2020-11-17),

Title: The Innovative Journey of Richard B. Silverman

Introduction: Richard B. Silverman, a distinguished inventor hailing from Winnetka, IL (US), has made significant contributions to the field of innovation with his groundbreaking work.

Latest Patents: Richard B. Silverman holds several patents in the field of pharmaceuticals and organic chemistry, with his most recent patent focusing on novel drug compounds for the treatment of neurological disorders.

Career Highlights: Throughout his illustrious career, Richard B. Silverman has been a trailblazer in the development of new drugs and treatments. His work has led to the creation of life-saving medications and therapies that have positively impacted countless lives around the world.

Collaborations: Richard B. Silverman has collaborated with leading researchers, scientists, and pharmaceutical companies to further his research and bring his inventions to market. His collaborative efforts have been instrumental in advancing the field of pharmaceuticals.

Conclusion: In conclusion, Richard B. Silverman's dedication to innovation and his pioneering spirit have solidified his legacy as a visionary inventor in the field of pharmaceuticals. His contributions continue to shape the landscape of modern medicine, making the world a better place for all.

This text is generated by artificial intelligence and may not be accurate.